Ubamatamab With Chemotherapy for Advanced Ovarian Cancer
Treatments studied
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This trial tests a new drug called ubamatamab combined with standard chemotherapy for advanced ovarian cancer that didn't respond well to initial treatment. It's designed for patients whose cancer is hard to remove surgically and didn't shrink enough with first-line chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Confirmed high-grade epithelial ovarian, fallopian tube, or peritoneal cancer (stage III or IV)
- Completed 3–4 cycles of standard carboplatin-paclitaxel chemotherapy as first-line treatment
- Cancer shows poor response to chemotherapy (low KELIM score) and cannot be completely removed by surgery
- Adequate blood counts, kidney, liver, and heart function
- No prior treatment with bevacizumab, immunotherapy, or other experimental cancer drugs
- Willingness to use effective contraception and comply with study visits and blood tests
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new combination treatment (ubamatamab plus another drug) for people with ovarian cancer that no longer responds to platinum chemotherapy. It could be an option if your cancer has kept growing despite prior treatment.
This trial tests adding trastuzumab to standard maintenance therapy with bevacizumab for patients with newly diagnosed advanced ovarian, fallopian tube, or primary peritoneal cancer. The goal is to see if the combination helps keep the cancer from growing longer.
This trial tests a combination treatment for advanced ovarian cancer that hasn't been treated before. It combines chemotherapy, a personalized vaccine made from your own immune cells, and a drug called pembrolizumab to help your immune system fight the cancer.
This trial tests a new targeted drug, SHR-A1811, combined with chemotherapy for women whose ovarian cancer has returned but still responds to platinum-based drugs. The goal is to see if the combination works better than chemotherapy alone.
This early-phase study tests ubamatamab, a cancer-targeting antibody, given by itself or with cemiplimab. It is meant to treat adults whose cancer has come back and who may not have other good standard options left.
This trial tests a combination of two immunotherapy drugs (iparomlimab and tovorilimab) plus bevacizumab and chemotherapy before surgery for advanced ovarian cancer that cannot be removed surgically at first. The goal is to see if this treatment can shrink the tumor enough to allow surgery.
Hear when a new Ovarian cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.